Stem Cells and Diseases
The Promise of Stem Cells
Studying stem cells will help us understand how they transform into the dazzling array of specialized cells that make us what we are. Some of the most serious medical conditions, such as cancer and birth defects, are due to problems that occur somewhere in this process. A better understanding of normal cell development will allow us to understand and perhaps correct the errors that cause these medical conditions.
Another potential application of stem cells is making cells and tissues for medical therapies. Today, donated organs and tissues are often used to replace those that are diseased or destroyed. Unfortunately, the number of people needing a transplant far exceeds the number of organs available for transplantation. Pluripotent stem cells offer the possibility of a renewable source of replacement cells and tissues to treat a myriad of diseases, conditions, and disabilities including Parkinson's disease, amyotrophic lateral sclerosis, spinal cord injury, burns, heart disease, diabetes, and arthritis.
Clinical Trials for Stem Cell Therapies
Human embryonic stem cells:
Scientists have been able to do experiments with human embryonic stem cells (hESC) since 1998, when a group led by Dr. James Thomson at the University of Wisconsin developed a technique to isolate and grow the cells. Although hESCs are thought to offer potential cures and therapies for many devastating diseases, research using them is still in its basic stages. hESCs are thought to offer potential cures and therapies for many devastating diseases, and we are now seeing the first clinical trials using cells derived from hESCs.
The NIH funded its first basic research study on hESCs in 2002. Since that time, biotechnology companies have built upon those basic foundations to begin developing stem cell-based human therapies. There are currently two active clinical trials using cells derived from human embryonic stem cells, both being conducted by a biotechnology company called ACT. The company has laboratories in Marlborough, Massachusetts and corporate offices in Santa Monica, California. ACT has begun enrolling patients for Phase I (safety and tolerability) clinical trials of two hESC-derived stem cell products:
- The first ACT trial is testing the safety of hESC-derived retinal cells to treat patients with an eye disease called Stargardt's Macular Dystrophy (SMD).
- The second ACT trial is testing the safety of hESC-derived retinal cells to treat patients with age-related macular degeneration.
In January, 2012, the investigators published a preliminary report on the first two patients treated with hESC-derived cells: http://www.ncbi.nlm.nih.gov/pubmed/22281388. A third patient was treated on April 20, 2012.
- Pfizer Inc. is planning to launch a study in collaboration with University College of London to test hESC-derived stem cell treatment for acute wet age-related macular degeneration. This study is not yet recruiting participants.
- A third clinical trial using hESC-derived cells was halted on November 14, 2011. The trial was being conducted by a biotechnology company called Geron, located in Menlo Park, California. Four patients with recent spinal cord injuries had been enrolled for its clinical trial of a hESC-derived therapy. The trial was testing the safety of using hESC-derived cells to achieve restoration of spinal cord function. Oligodendrocyte progenitor cells derived from hESCs were being injected directly into the lesion site of the patient's injured spinal cord. On November 14, Geron announced that it was discontinuing its stem cell programs to concentrate on cancer programs.
Human induced pluripotent stem cells:
Late in 2007, scientists reported that they had been able to reprogram adult human skin cells to behave like hESCs. This type of stem cells is known as induced pluripotent stem cells, or iPSCs. Since these first reports, researchers have rapidly improved the techniques to generate iPSCs, creating a powerful new way to "de-differentiate" cells whose developmental fates were thought to be determined.
In July 2013, Japan’s health minister approved the first clinical trial using cells derived from iPSCs. Masayo Takahashiin Kobe, Japan will use the cells to attempt to treat a form of blindness&8212;age-related macular degeneration.
Bone marrow stem cells:
Bone marrow contains blood-forming stem cells (hematopoietic stem cells) that have been used for decades to treat blood cancers and other blood disorders. Umbilical cord blood is another source of hematopoietic stem cells that is being used in treatment. You can see a list of diseases that may currently be treated with hematopoietic stem cells at the website of the National Marrow Donor Program. You may also search for clinical trials testing "bone marrow stem cells" or "umbilical cord blood" on the ClinicalTrials.gov website.
Human Central Nervous System Stem Cells (HuCNS-SCs):
A biotechnology company called Stem Cells Inc. (corporate headquarters in Newark, CA) is currently recruting participants for a Phase1/2 study of Human Central Nervous System Stem Cells (HuCNS-SC) in age-related macular degeneration (AMD).
Human spinal cord stem cells:
A biotechnology company called Neuralstem (corporate headquarters in Rockville, Maryland) is conducting a clinical trial testing the use of human spinal cord stem cells to treat Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease. The company obtained FDA approval to conduct a Phase I trial (safety and tolerability study) and began enrolling patients in January 2010. Twelve participants have received lumbar transplants, and in March 2012, the second participant received an injection in the cervial region. Details about this trial are listed on the ClinicalTrials.gov website.
Human mesenchymal stem cells:
Osiris Therapeutics (Columbia, Maryland) is conducting three different Phase 2 clinical trials with a product from adult mesenchymal cells (called Prochymal). The three trials are for:
- protecting pancreatic beta islet cells in adults and children with newly diagnosed type 1 diabetes (in partnership with the Juvenile Diabetes Research Foundation),
- repair of heart tissue following a heart attack, and
- the repair of lung tissue in patients with chronic obstructive pulmonary disease (COPD).
Osiris is also conducting Phase 3 testing of Prochymal for acute graft versus host disease (GvHD) and Crohn's disease.
Adult Eye Stem Cells for Eye Disease or Damage:
The limbus is the marginal region of the cornea of the eye that contains stem cells. Stem cells from the limbus are called limbal stem cells, and they normally serve to replace cells to maintain the cornea. Limbal stem cells are being tested as possible treatments for human eye conditions. Currently, scientists are testing whether limbal stem cells can help repair damage to the cornea and whether they can help replace cells that are lacking due to limbal stem cell deficiency.
Participating in Clinical Trials
Scientists are testing the abilities of many different types of stem cells to treat certain diseases. You can search for clinical trials using stem cells (or other methods) to treat a specific disease at ClinicalTrials.gov.